BPC-157: What the Human Evidence Actually Is
BPC-157 has an enormous following and, after two decades of interest, no published randomised human efficacy trial. Here is the rodent work, the regulatory record, and what the gap means.
Research Peptides
6 articles
Compounds sold for human use that have never been approved for it — and what evidence, if any, sits behind them.
Ipamorelin and CJC-1295: What GH Secretagogues Actually Do
Ipamorelin, CJC-1295 and their relatives raise the body's own growth hormone rather than replacing it. That changes the ceiling, the side effects, and what the evidence can honestly support.
GHK-Cu: Good Topical Evidence, Weak Injectable Case
Topical GHK-Cu has controlled cosmetic and wound-healing data behind it. The injectable version sold online has none, and it adds a copper-loading question the cream never has to answer.
Melanotan II: The Tan and the Melanoma Question
Melanotan II is an unlicensed melanocortin agonist sold for tanning. Here is what the case literature on new and changing moles does and does not establish, and how afamelanotide differs.
MOTS-c and the Mitochondrial Peptides: The Translation Gap
Mitochondrial-derived peptides have real biology and almost no human efficacy data. Elamipretide's trial record, failures included, shows what an actual development path looks like.
TB-500 and Thymosin Beta-4: The Trial Programme and the Grey Market
Thymosin beta-4 has completed randomised human trials. Almost all of them used the full 43-amino-acid protein, dosed into the eye. The TB-500 sold for injection is not that molecule.